JP2023528454A5 - - Google Patents
Info
- Publication number
- JP2023528454A5 JP2023528454A5 JP2022574398A JP2022574398A JP2023528454A5 JP 2023528454 A5 JP2023528454 A5 JP 2023528454A5 JP 2022574398 A JP2022574398 A JP 2022574398A JP 2022574398 A JP2022574398 A JP 2022574398A JP 2023528454 A5 JP2023528454 A5 JP 2023528454A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- gal
- fgfr2
- biparatope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063033975P | 2020-06-03 | 2020-06-03 | |
| US63/033,975 | 2020-06-03 | ||
| PCT/US2021/035468 WO2021247718A1 (en) | 2020-06-03 | 2021-06-02 | Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023528454A JP2023528454A (ja) | 2023-07-04 |
| JP2023528454A5 true JP2023528454A5 (https=) | 2024-06-10 |
Family
ID=78829919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574398A Pending JP2023528454A (ja) | 2020-06-03 | 2021-06-02 | 線維芽細胞増殖因子受容体２に特異的に結合する二重パラトープアンタゴニスト抗体およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230295308A1 (https=) |
| EP (1) | EP4161566A4 (https=) |
| JP (1) | JP2023528454A (https=) |
| CN (1) | CN116367855A (https=) |
| AU (1) | AU2021284297A1 (https=) |
| CA (1) | CA3185812A1 (https=) |
| WO (1) | WO2021247718A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250148746A (ko) * | 2023-01-13 | 2025-10-14 | 리제너론 파아마슈티컬스, 인크. | Fgfr3 결합 분자 및 그의 사용 방법 |
| CN118852431A (zh) * | 2023-04-28 | 2024-10-29 | 武汉人福创新药物研发中心有限公司 | 抗FGFR2b单抗 |
| WO2025070733A1 (en) * | 2023-09-29 | 2025-04-03 | Chugai Seiyaku Kabushiki Kaisha | Anti-rtk antibodies and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2083081A1 (en) * | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| HUE035700T2 (en) * | 2008-11-07 | 2018-05-28 | Galaxy Biotech Llc | Monoclonal antibodies to Fibroblast Growth Factor receptor 2 |
| AR088941A1 (es) * | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| US9498532B2 (en) * | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| AU2014357292B2 (en) * | 2013-11-27 | 2020-06-25 | Zymeworks Bc Inc. | Bispecific antigen-binding constructs targeting HER2 |
| CA2961439A1 (en) * | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| CN107446045A (zh) * | 2016-07-22 | 2017-12-08 | 北京天广实生物技术股份有限公司 | 一种抗her2的抗体、其药物组合物及用途 |
| MX2019005552A (es) * | 2016-11-14 | 2019-08-12 | Amgen Inc | Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas. |
-
2021
- 2021-06-02 CA CA3185812A patent/CA3185812A1/en active Pending
- 2021-06-02 JP JP2022574398A patent/JP2023528454A/ja active Pending
- 2021-06-02 AU AU2021284297A patent/AU2021284297A1/en active Pending
- 2021-06-02 CN CN202180056915.2A patent/CN116367855A/zh active Pending
- 2021-06-02 US US18/008,108 patent/US20230295308A1/en active Pending
- 2021-06-02 WO PCT/US2021/035468 patent/WO2021247718A1/en not_active Ceased
- 2021-06-02 EP EP21817362.3A patent/EP4161566A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7854016B2 (ja) | 腫瘍治療薬及びその応用 | |
| JP6900354B2 (ja) | 癌治療のための二重特異性ｈｅｒ２リガンド | |
| JP2023528454A5 (https=) | ||
| JP2020063262A5 (https=) | ||
| Djordjevic et al. | Targeting VEGF signalling via the neuropilin co-receptor | |
| Mitri et al. | The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy | |
| JP2022017219A (ja) | 増殖分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体 | |
| JP2020521478A5 (https=) | ||
| CN103965363B (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| US20220372150A1 (en) | Anti-pd-l1 single-domain antibodies | |
| JP2013527761A5 (https=) | ||
| Chen et al. | A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy | |
| JP2018502050A5 (https=) | ||
| CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| JP2020513855A5 (https=) | ||
| JP2018509887A5 (https=) | ||
| JP2022515868A5 (https=) | ||
| JP2022517920A5 (https=) | ||
| WO2013123861A1 (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2023544143A5 (https=) | ||
| CN108430511A (zh) | 一种药物设计方法和获得的药物及其应用 | |
| KR20150083840A (ko) | Her3 결합 폴리펩티드 | |
| CN115605513A (zh) | 一种抗pd-l1和her2的双特异性抗体 | |
| JP2025503731A5 (https=) | ||
| CN111848805B (zh) | 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体 |